Dendrimers

Jain, Keerti

doi:10.1016/b978-0-08-101914-6.00007-7

Cited by 21 publications

(4 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemical and physiological properties of dendrimers depend on their monomers, generations (size), terminal groups, and synthetic routes. These parameters can be modified by dendrimers with specific properties for application in different biomedical fields [ 85 ]. While their characteristic properties vary, they have numerous characteristics that make them distinctive from other drug carriers.…”

Section: Dendrimersmentioning

confidence: 99%

Anti-biofilm, drug delivery and cytotoxicity properties of dendrimers

Ezeh,

Dibua

2024

ADMET DMPK

View full text Add to dashboard Cite

Background and purpose: Treatments using antimicrobial agents have faced many difficulties as a result of biofilm formation by pathogenic microorganisms. The biofilm matrix formed by these microorganisms prevents antimicrobial agents from penetrating the interior where they can exact their activity effectively. Additionally, extracellular polymeric molecules associated with biofilm surfaces can absorb antimicrobial compounds, lowering their bioavailability. This problem has resulted in the quest for alternative treatment protocols, and the development of nanomaterials and devices through nanotechnology has recently been on the rise. Research approach: The literature on dendrimers was searched for in databases such as Google Scholar, PubMed, and ScienceDirect. Key results: As a nanomaterial, dendrimers have found useful applications as a drug delivery vehicle for antimicrobial agents against biofilm-mediated infections to circumvent these defense mechanisms. The distinctive properties of dendrimers, such as multi-valency, biocompatibility, high water solubility, non-immunogenicity, and biofilm matrix-/cell membrane fusogenicity (ability to merge with intracellular membrane or other proteins), significantly increase the efficacy of antimicrobial agents and reduce the likelihood of recurring infections. Conclusion: This review outlines the current state of dendrimer carriers for biofilm treatments, provides examples of their real-world uses, and examines potential drawbacks.

show abstract

Section: Dendrimersmentioning

confidence: 99%

Anti-biofilm, drug delivery and cytotoxicity properties of dendrimers

Ezeh,

Dibua

2024

ADMET DMPK

View full text Add to dashboard Cite

show abstract

“…The antiangiogenic therapy is an effective strategy for cancer treatment and identification of biomarkers for angiogenesis could be the future for development of antiangiogenic drugs. Various strategies have been explored for targeted delivery of these drugs [ 51 , 52 ]. Generally, angiogenic biomarkers are involved with initiation, progression, and metastasis of cancer and targeting these biomarkers could modulate the angiogenesis in cancerous cells.…”

Section: Prognostic and Therapeutic Angiogenic Biomarkersmentioning

confidence: 99%

Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies

Pathak,

Pal,

Roy

et al. 2024

Stem Cells International

Self Cite

View full text Add to dashboard Cite

Angiogenesis plays a significant role in the human body, from wound healing to tumor progression. “Angiogenic switch” indicates a time-restricted event where the imbalance between pro- and antiangiogenic factors results in the transition from prevascular hyperplasia to outgrowing vascularized tumor, which eventually leads to the malignant cancer progression. In the last decade, molecular players, i.e., angiogenic biomarkers and underlying molecular pathways involved in tumorigenesis, have been intensely investigated. Disrupting the initiation and halting the progression of angiogenesis by targeting these biomarkers and molecular pathways has been considered as a potential treatment approach for tumor angiogenesis. This review discusses the currently known biomarkers and available antiangiogenic therapies in cancer, i.e., monoclonal antibodies, aptamers, small molecular inhibitors, miRNAs, siRNAs, angiostatin, endostatin, and melatonin analogues, either approved by the U.S. Food and Drug Administration or currently under clinical and preclinical investigations.

show abstract

“…Some examples of these polymers focus predominantly in the area of biotechnology, in biomedical and environmental applications in which dendrimers for controlled release of chemical species play a special role [56]. Azopolymers for Figure 2.…”

Section: Incorporation Of Nanoparticles In Technical Textilesmentioning

confidence: 99%

Nanocomposite and biodegradable polymers applied to technical textiles

Caicedo

Melo-López

Cabello-Alvarado

et al. 2019

DYNA

View full text Add to dashboard Cite

Based on the results of research papers reflected in the scientific literature, the main examples, methods and perspectives for the development of technical textiles are considered. The focus of this work is to concentrate the results obtained for different textile applications (technical textiles) through the use of biodegradable polymers modified and improved with nanoparticles. The techniques for obtaining polymeric nanocomposites, finishing processes, type and structure of textiles are specified. In general, key aspects are identified for a better understanding of the technical challenges and physicochemical effects of the fibers.

show abstract

Dendrimers

Cited by 21 publications

References 167 publications

Anti-biofilm, drug delivery and cytotoxicity properties of dendrimers

Anti-biofilm, drug delivery and cytotoxicity properties of dendrimers

Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies

Nanocomposite and biodegradable polymers applied to technical textiles

Contact Info

Product

Resources

About